SK Biopharmaceuticals Co Ltd 2022 Sustainability Report
Company: SK Biopharmaceuticals Co Ltd
Sector: Manufacturing
Country: South Korea
Year: 2022
Type: Sustainability Report
Pages: 94
The report highlights KRW 296.4 billion in 2022 social value generated through XCOPRI sales, a company-wide Net-Zero roadmap targeting 2040, and disclosure of 2022 Scope 1, Scope 2 and partially covered Scope 3 emissions. It also describes Board-level ESG oversight, ISO 14001 environmental management, employee training, human-rights programs and diversity initiatives.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.